Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Provence Technologies Launches New USD 1.7 Million Research Programme

Published: Tuesday, January 29, 2013
Last Updated: Monday, January 28, 2013
Bookmark and Share
Screening 1000, the research project conducted by Provence Technologies, is set up to find and market a new ultra-pure molecule.

Provence Technologies has announced the launch of Screening 1000, a new USD 1.7 million (EUR 1.3 million) research programme with the goal of discovering a new ultra-pure molecule for the healthcare market.

The project is being launched by the R&D department of Provence Technologies and is being co-financed equally by Oseo, the French innovation promotion agency and Provence Technologies.

The programme is planned to run for two years and aims to develop a new range of products.

Screening 1000 will firstly analyze 1000 chemical compounds already on the market and detect those that show anomalies in purity. The use of already known compounds allows an existing range to be optimized, thereby reducing development costs.

Provence Technologies will then focus on new compounds with the most promising market potential. To help achieve this, the company will develop new approaches to purification and synthesis, making it possible to meet the purity levels required by health regulations.

“We hope this research project will create as much success as Provence Technologies enjoyed with our efforts around methylene blue. The really innovative part of this program is implementing new solutions in the fields of purification of active principles or alternative synthesis pathways,” said Claude Monteils, internal R&D project coordinator, Provence Technologies.

Monteils continued, “We are delighted that the French innovation promotion agency Oseo, which is a traditional partner of Provence Technologies, is joining us in this highly promising project and again supporting us in our strategy of innovation.”

“As well as providing R&D services in the field of fine chemistry, Provence Technologies will continue to develop its own internal research projects and proprietary research efforts,” said Dr Babak Sayah, chief operating officer, Provence Technologies.

Dr Sayah continued, “This new programme demonstrates the high added value of our own technologies in finding new uses for molecules, both old and new, in response to increasingly high stakes in public health.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Provence Technologies Acquires Synprosis
The acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistry.
Tuesday, June 03, 2014
Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office
The group will also use the investment to set up an incubator for health care industry start-ups.
Thursday, January 30, 2014
Provence Technologies Increases its Capital to EUR One Million
Underpinned by a stronger financial structure, the company will develop new projects for rehabilitating compounds of proven therapeutic potential.
Thursday, September 06, 2012
Provence and Neuroptis Biotech Partner to Develop a New Compound for Treating Dry Eye Syndrome
Provence Technologies to optimize and transfer the production process for ML7, Neuroptis Biotech’s dry eye drug candidate.
Wednesday, May 23, 2012
Provence Technologies and NexGenix Announce Successful Lead Compound Development
Both companies have been collaborating on the synthesis optimization and pre industrialization of innovative molecule targeting Hsp90.
Wednesday, July 06, 2011
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos